Incyte (INCY) AI Stock Analysis

Incyte

(BMV:INCY)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Broad-based revenue growth and core-business diversificationGrowth is broadening beyond Jakafi, reducing reliance on a single established product and creating a more diversified commercial base. The 30% expansion in the core business, supported by several marketed medicines, strengthens the company’s ability to compound revenue over the next several quarters.

Negative Factors

Recent free-cash-flow deteriorationAlthough cash generation remains positive, the sharp TTM decline indicates that earnings are converting into cash less consistently than in the prior period. Continued volatility could constrain internally funded investment and make operating performance less predictable while the company advances several costly development programs.

Incyte (INCY) vs. SPDR S&P 500 ETF (SPY)

Market Cap: MXN 24.40B
Dividend Yield: ―
Average Volume (3M): 671
Price to Earnings (P/E): 57.3
Beta (1Y): 0.06
Revenue Growth: 12.27%
EPS Growth: -67.48%
Country: Mexico
Employees: 2,844
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Incyte Business Overview & Revenue Model

Company Description

Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a f...

Incyte Earnings Call Summary

Earnings Call Date:Oct 28, 2026(Q3-2026)|% Change Since:0.00%|Next Earnings Date:Feb 08, 2027

Earnings Call SentimentPositive

The call was strongly positive, characterized by 14% quarterly revenue and net sales growth, broad-based product demand, raised full-year sales guidance, regulatory progress, and substantial expansion of the late-stage pipeline. The main negatives were the large Vega-related GAAP expense increase, pricing-related moderation in reported Jakafi growth, the discontinuation of the platinum-resistant ovarian cancer CDK2 study, and some pending clinical and regulatory milestones. Highlights significantly outweighed lowlights.

Positive Updates

Strong Third-Quarter Revenue and Net Sales Growth

Total revenue was $1.56 billion, up 14% year-over-year, while total net sales were $1.32 billion, also up 14%, driven by strong product demand and broad-based growth led by OPZELURA and the hematology and oncology franchise.

Negative Updates

GAAP Expenses Increased Sharply Due to Vega Acquisition

Total GAAP expenses were $2.27 billion, up 146% year-over-year, including a $1.23 billion IPR&D expense related to the Vega acquisition. GAAP R&D expenses were $1.79 billion, up 254%, driven by the acquisition and continued investment in late-stage assets.

Company Guidance

Management expects XR net sales of roughly $50 million by year-end and aims to retain 10%-30% of the Jakafi business by 2029; core business excluding Jakafi is expected to grow to $3 billion-$4 billion by 2030. Full-year 2026 net sales guidance was raised to $1.1 billion-$1.12 billion for OPZELURA, $890 million-$910 million for hematology and oncology, and $5.210 billion-$5.300 billion in total, while total R&D and SG&A expenses are expected to be towards the middle of the full-year range and COGS is expected to be approximately 8% for the full year. Management expects a potential povorcitinib approval in Europe by year-end and U.S. approval in the first quarter of 2027, first-line 989 clinical data by year-end, next-generation mutant CALR antibody clinical entry in early 2027, next-generation V617F clinical entry in early 2027, pivotal trials with next-generation CALR antibody in 2028, and top-line data for latarcibart in early 2029; OPZELURA in mild to moderate HS could produce a 5%-10% lift and $50 million, $100 million in incremental sales, although it is not necessarily built into models right now.

Incyte Risk Analysis

Incyte disclosed 40 risk factors in its most recent earnings report. Incyte reported the most risks in the "Legal & Regulatory" category.

Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

1 New Risk

1.Changes in government pricing policies, including the enactment of "most favored nation" pricing legislation, could adversely affect our business.Q4, 2025

Incyte Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

MX:INCY against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ONC	85Outperform	$41.40B	25.05	14.27%	―	34.39%	―
EXEL	81Outperform	$16.93B	20.11	45.54%	―	9.12%	40.53%
TGTX	73Outperform	$9.36B	20.09	72.30%	―	76.08%	634.54%
GMAB	71Outperform	$34.94B	45.64	13.58%	―	21.75%	-36.69%
JAZZ	65Neutral	$14.02B	14.21	21.37%	―	12.59%	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

MX:INCY and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
MX:INCY	Incyte	1988.32	254.32	14.67%
EXEL	Exelixis	69.39	31.33	82.32%
JAZZ	Jazz Pharmaceuticals	215.98	77.60	56.08%
TGTX	TG Therapeutics	61.18	27.49	81.60%
ONC	BeOne Medicines	370.33	58.47	18.75%
GMAB	Genmab (Otc)	57.06	28.35	98.75%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Incyte AI Stock Analysis